President, Operations, Mankind
Mr. Abhay is a seasoned leader with a remarkable blend of academic and professional accomplishments. He holds a B.Pharm and an MBA degree, and is also a Certified Six Sigma Black Belt and an Executive Alumnus of the prestigious Indian Institute of Management, Lucknow. Mr. Abhay has held various leadership roles in renowned organizations such as USV, ALKEM, and Sun Pharma. Currently, he is with Mankind Pharma, where he is responsible for driving the overall manufacturing strategy and transformation across all Operations Verticals. As a forward-thinking leader, Mr. Abhay is committed to creating agility in Mankind’s operations by undertaking disruptive process transformations through operational excellence and embracing digital transformation across all aspects of the supply chain.
Global Chief Human Resources, Intas
President Human Resources, leading HR at Intas and its global subsidiaries Accord Healthcare in Europe, North America, Latin America and rest of Emerging markets. Intas operates across 86+ countries with employee base of 24000+ & turnover over 2.5 Bn USD.
Strong business process understanding with robust experience of leading and driving change, acceleration and integration in large, complex and fast-growing organizations.
Excellent track record of 30+ years as HR leader of pharmaceutical industry for top Global MNCs like Abbott in India and Basel ( Switzerland) and with Indian MNCs like Sun , Zydus and Torrent where he partnered with business across India, Europe , US and Latin Americas.
Expertise in developing and delivering large scale change management programme including talent strategy, sales force transformation, quality culture reinforcement, mergers and acquisitions, green field startup ups, strategic employee relations management, organization restructuring and reorganizing.
Director, Foundation for Pharma Academy for Global Excellence (PAGE)
Amitava (Amit) is an alumnus of IIM, Calcutta and Delhi College of Engg., Delhi University. He started his career in Marketing and then shifted to HR with Infosys in 2000. Since then, he has worked with Accenture, Mashreq Bank, Firstsource Solutions and Biocon leading global teams across multiple COEs of HR. Currently he is the Head of PAGE (Pharma Academy of Global Excellence) which is a skill building institute for Indian Pharma industry. He is passionate about building organisations and the talent pool to support the same.
Sr Partner & Lead, India Life Sciences, McKinsey & Co
Ankur Bhajanka based out of Mckinsey & Co.’s Mumbai office, Ankur leads the Healthcare practice in India and the Generics Pharma practice globally.
Over last 17 years with the firm, Ankur has worked with multiple leading generics players, both in India and globally, and has helped companies thinks through their overall strategy and organization setup, driven performance transformation across the value chain (right from R&D, to Operations, to commercial), and has helped players build new businesses/ capabilities (e.g. in digital/ analytics).
Ankur holds an MBA from IIM Indore and a B.Tech in Computer science from NIT Allahabad.
Managing Director and Head, Healthcare Investment Banking, Avendus Capital
Anshul is a seasoned dealmaker with 20+ years of investment banking experience and has established himself as trusted advisor in pharma and healthcare. He has successfully led 50+ transactions across sectors such as healthcare, pharma, industrials, and consumer. Anshul was previously Managing Director at Citi Investment Banking where he was heading the healthcare, consumer, industrials, and M&A practice.
He holds an MBA degree from the University of Chicago’s Booth School of Business and an engineering degree from IIT, Delhi
President Biotechnology, Lupin
Cyrus Karkaria, a visionary leader, has been the President of the Biotechnology division of Lupin since 2010 and is based at Pune. He has over 30 years of rich industry experience in the field of Bio-pharmaceutical drug development while working with multi-national companies based out of US and India
Under his leadership at Lupin, regulatory and clinical strategies are formulated with a strong focus on harmonization of global regulatory guidelines and commercialization strategies designed based on the complex regulatory, IP and competitive landscape. He has been instrumental in establishing a global footprint for Lupin Biotech, by adopting quality framework in line with stringent global norms, adapting quickly to the changing global landscape and reinventing business models by promoting a creative and flexible organization culture.
Before Lupin, he was Vice President at Celldex Therapeutics and CuraGen Corporation in New Haven, Connecticut, USA heading Operations and Biopharmaceutical Process Sciences. He has also held positions at Biogen Idec and Scios and has been part of teams that have developed blockbusters in the field of neurology, immunology and oncology such as Avonex, Amevive and Tysabri (Biogen Idec). Such background experiences have helped create his expertise and proficiency in development and commercialization of biologic products.
He holds a Ph.D. in Biochemistry from the University of Maryland and was a post- doctoral researcher at the Harvard Medical School.
Founder Chairman and Managing Director, Sun Pharmaceutical Industries
Dilip Shanghvi, 69, is the Chairman and Managing Director of Sun Pharmaceutical Industries Limited (Sun Pharma), world’s 4th largest and India’s No. 1 specialty generic pharmaceutical company. He is also the Chairman of Sun Pharma Advanced Research Company Ltd., which is engaged in R&D of new innovative drugs and delivery technologies.
Mr Shanghvi was honoured with India’s fourth highest civilian award, the Padma Shri, in recognition of his distinguished contribution to the Indian Trade & Industry, in 2016. He is part of the Economic Advisory Council formed by the Government of Maharashtra, India to achieve rapid and comprehensive development in the state. The Government of Gujarat, India appointed him as the Chairman of Gujarat Biotechnology University in 2022.
Mr Shanghvi has been conferred with many awards and recognitions. In 2024, the Institute of Directors in India conferred the award of ”Distinguished Fellowship” to Mr Shanghvi for his outstanding contribution to public service and society. In 2023, 2021 & 2020, India’s leading magazine, India Today included him in its
Annual Power List of 50 influential personalities in India. Some of the other awards and recognitions bestowed on him include: Moneycontrol Lifetime Achievement Award (2023), All India Management Association (AIMA) Entrepreneur of the Year (2017), NDTV Business Leader of the Year (2015), Forbes Entrepreneur for the year (2014), Economic Times’ Business Leader of the Year (2014), CNN IBN’s Indian of the Year – Business (2011), Business India’s Businessman of the Year (2011) and Ernst and Young’s World Entrepreneur of the Year (2011). He has also been awarded the Economic Times’ Entrepreneur of the Year (2008), Business Standard’s CEO of the Year (2008) and CNBC TV 18’s First Generation Entrepreneur of the Year (2007)
He is a former President of the Indian Pharmaceutical Alliance (IPA) and has also served as the chairman of the Board of Governors of the Indian Institute of Technology (Bombay). He has been a member of the board committee of the Reserve Bank of India, India’s central bank and is a former trustee of the Rhodes Scholarship Program at Oxford University.
In 2019, he was conferred with an honorary doctorate by the Tel Aviv University, Israel’s largest and most comprehensive institution of higher learning.
Mr Shanghvi has played a vital role in the globalisation of the Indian pharmaceutical industry and continues to inspire generations of entrepreneurs in their journey to success.
Hon'ble Member - NITI Aayog, Government of India
Dr. Arvind Virmani is a Member of NITI Aayog. He specialises in policy & institutional reforms for sustained, fast inclusive economic growth.
He is a macro economist who has bridged the gap between academics, think tanks and policy makers, through research based policy advice and policy oriented research. He played a prominent, professional and advisory role in the economic reforms of the 1990s and 2000s, such as Tax, Tariff, Foreign Exchange, Financial Sector & Expenditure Policy reforms.
He was the founder Chairman of the “Foundation for Economic Growth and Welfare” (EGROW) and President of the Forum for Strategic Initiatives (FSI, Delhi) and has earlier served as Executive Director, IMF, Chief Economic Advisor, Ministry of Finance and Principal Advisor, Planning Commission.
He was Director & Chief Executive of ICRIER and has published over 60 Journal Articles, Books & Chapters, and more than 100 Working and Policy Papers in Macroeconomics, Growth, Tax & Tariff Reform, Foreign Exchange, International Relations and National Security Strategy.
He was a member of the TRAI, a mentor (Public Policy & Economics) to FICCI, and Member of Technical Advisory Committee on Monetary Policy, RBI.
His experience in Finance Sector includes: Chairman, Board of Trustees of SBI Mutual Fund, Director LIC, Member of SEBI Appellate Tribunal and Depositories Act, Member Board of Trustee at UTI and Director in PNB, Allahabad Bank and EXIM Bank.
His Think Tank experience includes: Member, Board of Governors in CPR & RIS, Non-resident Sr. Fellow in Brooking Institution, USA, Affiliate Professor & Distinguished Sr. Fellow in George Mason University, USA.
Director, NIPER Mohali
Prof. Panda is serving as the Director of NIPER Mohali, before joining NIPER Mohali, he was serving as an Institute Chair Professor in the Department of Biosciences & Bioengineering, at the Indian Institute of Technology, Bombay. His research areas include pharmacology, cell biology, biophysics, and biochemistry.
He is a J.C. Bose National Fellow, fellow of the World Academy of Sciences, and fellow of all three National Sciences Academies of India; Indian National Science Academy (INSA), Indian Academy of Sciences (IAS), & National Academy of Sciences India (NASI). He was awarded the highly prestigious G. N. Ramachandran Gold Medal from the Council of Scientific and Industrial Research, Govt of India, Tata Innovation fellowship from the Department of Biotechnology, Govt of India, DAE-SRC outstanding research award, Department of Atomic Energy- Govt of India and Swarna Jayanti Fellowship from Department of Science & Technology, Govt of India, National Bioscience Award, DBT, India, Sun Pharma Research Award, CDRI-award for excellence in drug research and Fogarty international research award, NIH, USA. He has been awarded 9 (3 American and 6 Indian) patents.
CEO, Life Sciences Sector Skill Development Council
Goutam Bhattacharya is a pharmaceutical and healthcare professional with three decades of working experience in leading multinational pharmaceutical and medical device companies in India. Prior to joining Council, he has worked in senior leadership positions with companies in India like LG Life Sciences; Boston Scientific, Win-Medicare, having started his career as Medical Rep with Lupin Labs.
Goutam Bhattacharya is a pharmaceutical and healthcare professional with three decades of working experience in leading multinational pharmaceutical and medical device companies in India. Prior to joining Council, he has worked in senior leadership positions with companies in India like LG Life Sciences; Boston Scientific, Win-Medicare, having started his career as Medical Rep with Lupin Labs.
Goutam is a Bachelor of Science & MBA (Marketing) from Bhopal University. He has acquired deep domain knowledge in pharmaceuticals, biologics, medical devices, diagnostics, vaccines & agrochemicals sectors. He brings with him hands-on working experience in managing multi-disciplinary teams involved in business development & licensing of assets; CRAMS; co-marketing/ promotion; product sourcing; regulatory affairs; clinical trials and sales & marketing.
Head of Division Scientific Support and Inspections, EDQM
Dr Hilde Depraetere, PhD in Biochemistry from the University of Leuven, Belgium, has more than 20 years’ experience in regulatory affairs in Industry and non-for-profit organisations for both biologicals and APIs. Her main field of expertise is CMC and inspection related. In 2021 she joined the EDQM Certification of Substance department as Head of Scientific Support and Inspection.
CEO, Enzene Biosciences
Himanshu Gadgil, PhD brings with him 24 years of experience in the pharmaceutical industry. He is the Chief Executive Officer at Enzene Biosciences Ltd. presiding over all business functions of the company. Under his leadership, Enzene has grown from a start-up biotech to a multi-vertical, multi-site product development and manufacturing service-based biopharmaceutical company.
Previously, as Sr. Vice President at Intas Pharmaceutical Ltd., he revitalized the commercial product pipeline, launching several biosimilar products globally. During his stint in the US, he led different facets of process and product development at Amgen, spearheading IND, BLA and Market authorizations of various blockbuster biotech products. At the inception of his career, he joined Waters Corporation where he pioneered development of QBD enabling multi-attribute methodologies for biopharmaceutical characterization.
Himanshu holds a PhD in Biochemistry from University of Tennessee and is a passionate scientific leader and innovator with over 50 publications and patents.
Executive Director, Innovation and Compliance, MHRA
James Pound joined the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) in 2008. He has worked in a variety of roles within the MHRA and is an executive leader within the Agency with responsibility for our Innovation Accelerator (the home of our innovative pathways for medicines and medical devices), the clinical investigations and trials group and the standards and compliance function which includes our Medicines GXP compliance teams, British Pharmacopoeia and medical devices audit and compliance. James led the cross-Agency response to clinical trial assessment delays in 2023 which were successfully eliminated in Autumn 2023 with sustained performance by the Agency since then. He holds an honours degree in Chemistry and has previously worked in a variety of roles in development and manufacturing in the pharmaceutical industry.
Sr Director Reg Compliance, Sidley Austin LLP, (Ex-FDA)
Jay Jariwala is the senior director of regulatory compliance with a focus on pharmaceutical quality system compliance and enforcement matters. Prior to joining Sidley, Jay served as team leader/Combination Products subject matter expert within the Office of Compliance at the Center for Drug Evaluation and Research (CDER), a branch of the U.S. Food and Drug Administration (FDA).
For over 13 years, Jay served as an FDA regulator at multiple FDA centers, including CDER, the Center for Devices and Radiological Health (CDRH), and the Office of the Commissioner, applying the agency’s laws, regulations, guidance, and other technical and administrative policies on drugs, medical devices, and combination products to policy development, facility inspections, compliance, enforcement, and approval processes. His FDA leadership experience includes serving as assistant country director (Drugs) and supervisory Consumer Safety officer in the agency’s India Office (New Delhi). Jay also participated as a subject matter expert in many drug inspections with a focus on data integrity and Out-of-Specification (OOS) investigations.
Before shifting his FDA focus to drugs, Jay spent several years at CDRH working on compliance issues related to medical devices, including regulatory policy related to Quality System Regulation and advisory actions. During his time at CDRH, he held positions of increasing responsibility, including the role of Quality System Specialist, and worked with several international regulators to establish the Medical Device Single Audit Program.
As team leader / Combination Products subject matter expert, Jay led a large team of compliance officers within the Division of Drug Quality I, the Office of Manufacturing Quality (OMQ), the Office of Compliance, and the CDER. In addition to his responsibilities for resource planning and operational oversight for violative establishment inspection assessments and resulting regulatory actions, Jay trained FDA investigators on current good manufacturing practice (CGMP) requirements — particularly data integrity and quality investigations. In New Delhi, Jay managed a team of investigators for all facility inspections conducted by the India Office and compliance follow-up. He also liaised with foreign regulatory counterparts such as EU/EMA, EDQM, PMDA-Japan, and WHO to establish inspection synergies and the exchange of information. During his time, he spearheaded many advisory and administrative actions, such as Warning Letters, Import Alerts, Regulatory Meetings, Recalls, and Injunctions.
Due to his background in drug and medical devices, Jay was part of the FDA group responsible for developing CGMPs for combination products, guidance, internal training, and a compliance program. In OMQ, Jay advised on and assisted compliance officers and leadership in evaluating policies, inspectional matters, and resulting regulatory actions related to combination products.
A noted speaker on a broad variety of topics including facility inspections, data integrity, OOS investigations, quality culture, supply chain integrity, corrective and preventive actions, and globalization and compliance trends, Jay also holds several medical device- and drug-related teaching roles. He earned a bachelor’s degree in Mechanical Engineering from the National Institute of Technology in Surat, India, and a master’s degree in Mechanical Engineering from Kansas State University.
Director & VP, L&T Defence Business and President, Society of Indian Defence Manufacturers (SIDM)
Mr. J D Patil served as a Whole Time Director of L&T (Defence & Semiconductors). He is alumnus of IIT Mumbai, M. Tech (Mech Engg) 1978.
He is celebrated and featured among ‘100 Great IITians’ dedicated to the service of the Nation.
Mr Patil with ~5 decades of career in L&T, joined L&T’s Corporate R&D and spearheaded L&T’s foray’s in the Defence sector & oversaw evolution of Space business.
He also mentored the growth of Smart Cities, Safe Cities and Communication business of L&T with a focus on making our cities Smart and Safe.
In addition, Mr. Patil serves as
Executive Director and COO, USV
Mr Jayant Dwivedy is Executive Director and COO of USV Private Limited and a Board Member. He is a M.Tech from IIT, Kharagpur.
Mr. Dwivedy has more than 30 years of rich experience in Manufacturing and Operations, Global Supply Chain, Quality and Compliance Management, Business Process Re-Engineering, Project Management, ERP, Corporate Training & Business Development. He has keen interest in Management Systems, Operations, Digital Implementations and People Development. His earlier organizations include GlaxoSmithKline Pharmaceuticals, Piramal Healthcare and Meiji Medreich.
He has won several awards and is invited to speak at various forums. He has recently won Pharma Manufacturing Leader Award 2024. He has received media coverage in CNBC, Economic Times and Business World as an expert in Pharmaceutical business management.
Partner, Kaizen Hansei & Joint Managing Director for India, South Asia and Africa, Kaizen Institute
Jayanth is a student of KAIZENTM for over 25 years. He continues to support, shape, and grow Kaizen Institute’s footprints across Africa and South Asia. His passion and experience is in supporting organizations to explore, understand and make an informed decision regarding the need and relevance of KAIZENTM for their organizational development.
KAIZENTM and Operational Excellence/ Lean philosophy remain his core domain and he has motivated manufacturing and service organizations across thirty- plus countries to embrace the KAIZENTM Way!
In 1991 he established his consulting practice and in the year 2001, he was invited to join Kaizen Institute India as a partner and director. In the year 2005, they expanded to set up Kaizen Institute’s operations in Africa. He has pioneered KAIZENTM adoption for the Government of Mauritius, Kenya, Tanzania and India and also has the privilege to promote KAIZENTM within the office of the Prime Minister of India.
In partnership with the Bill & Melinda Gates Foundation, the Africa operations support over ten African countries to apply KAIZENTM in the distribution of medical commodities. Jayanth is an Industrial and Production Engineer who also received an AOTS Scholarship in 1996 to study Quality Management at KKC Osaka. He is a Fulbright Fellow (2005) from Carnegie Mellon University, USA.
He is a also recipient of the Monozukuri Jinzai Ambassador Citation from AoTS, Japan Government.
Director of Medicines Manufacturing Innovation Centre, Centre for Process Innovation (CPI), UK
John is the Director of the Medicines Manufacturing Innovation Centre, Glasgow, a collaboration between CPI, founding industry partners AstraZeneca and GSK, University of Strathclyde, UK Research & Innovation, Scottish Enterprise. Prior to joining CPI, John worked for GSK, joining the company in 1986 as a Process Chemist covering all aspects of the manufacturing supply chain from large scale fermentation, fine chemicals (including enzymatic conversions), Chemical Development and Secondary Sterile Operations.
After 10 years of site base roles his focus moved to Strategic leadership roles in Head Office. John has a Chemistry degree, an MBA from Strathclyde University Business School, Private Pilot and double decker bus licences.
Head, Global Quality & Pharmacovigilance, Dr Reddy’s Laboratories
Mr. Krishna Venkatesh is the Global Head of Quality & Pharmacovigilance at Dr. Reddy’s Laboratories. Mr. Venkatesh has over 28 years of experience in the pharmaceutical industry across areas of product development, process engineering, technology transfer and manufacturing operations. Mr. Venkatesh has graduated from Harvard Business School through the General Management Program, holds a Masters in Pharmaceutics from the University of Mississippi, and a B. Pharm degree from BITS Pilani. Mr. Venkatesh has been with Dr. Reddy’s for the last 14 years and is passionate about driving excellence and innovation across manufacturing and operations, while ensuring that the highest standards of quality are consistently maintained. Prior to joining Dr. Reddy’s, he worked with Barr Pharmaceuticals and Teva in the United States.
Principal Consultant, MTT Consulting LLC. Former Director U.S. FDA India Office & U.S. DHHS India Health Attaché
Dr Mathew T Thomas is a medical doctor who retired from USFDA after 34 plus years in regulatory, management, and leadership positions. He served as USFDA India Office Country Director (2015 to 2017), and as US Health Attache (2016 to 2017) in New Delhi.
He owns MTT Consulting LLC, an independent consulting firm for entities engaged in USFDA regulated product development. He is on the Board of Directors for IndoUSrare Organization, which promotes the development of products for rare diseases. He is a member of the Global Engagement and Outreach Network of the USFDA Alumni Association. He shares a wide range of other interests including a study of world religions, ecumenical engagements, motorcycle riding, sports, tailoring, and furthering cultural and community activities through theater acting, script writing, editing, and publishing.
Chair, Quality Committee, IPA and Managing Director, Lupin
Nilesh Gupta is a distinguished leader in the pharmaceutical industry and is the Managing Director and member of the board of Lupin. Nilesh joined Lupin in 1996 and has played a pivotal role in transforming the company into a global pharmaceutical major. He is a Chemical Engineer from the Institute of Chemical Technology, Mumbai and an MBA from the Wharton School, Philadelphia. As Managing Director of Lupin, Mr. Gupta co-leads the Company and has helped establish Lupin’s research platforms, expanded its manufacturing operations and strengthened its quality standards. Mr. Gupta is also responsible for the Company's R&D and Technical Operations, and leads the commercial function for the India, API, global institution and Asia Pacific regions, which are close to half of the company’s revenues. Lupin is a global pharmaceutical leader with revenues of over USD 2.5 billion, headquartered in Mumbai, India. Lupin has 15 manufacturing sites and 7 research centers globally, along with a workforce of over 23,000.
Chairman, Zydus Lifesciences
Mr. Pankaj Patel is the Chairman of Zydus Lifesciences Ltd., a discovery-driven, global Lifesciences company with operations in 55 countries worldwide. A stalwart and a visionary, Mr. Pankaj Patel combines both research and techno-commercial expertise. He has published over 100 research papers in peer reviewed journals and is a co-inventor in more than 64 patents. He has been conferred with Dsc. (Honoris Causa) by Dr. A.P.J. Abdul Kalam Technical University, Lucknow.
Mr. Patel has been appointed as the Non-official Director in Central Board of the Reserve Bank of India. He is on the board of several institutions, including Chairperson of the Board of Governors of IIM Ahmedabad and Chairman of IIM Udaipur and Invest India. He is also a Member of the Governing Board of India Pharmacopoeia Commission (IPC), Ministry of Health & Family Welfare, Government of India. He is also a Member of the CEO Advisory Committee of International Generics and Biosimilars Association (IGBA). Mr. Patel is a Past President of the Federation of Indian Chamber of Commerce & Industry (FICCI). He also officiates on the board of several Not-for-Profit & charitable institutions. Mr. Patel is the Executive Chairman of the Gujarat Cancer Society and Chairman of the Gujarat Cancer and Research Institute, a Regional Cancer Centre and one of the largest cancer centres of India, reaching out to the needy and underprivileged cancer patients. He also officiates as the Chairman of the Deaf and Mute School, Ahmedabad. He is also a Director and Chairman on the Board of Zydus Foundation which set up Zydus Hospital and Medical College, Dahod.
Mr. Pankaj Patel has been conferred with the prestigious Padma Bhushan for the year 2025 by the Government of India. In recognition of his contributions to the healthcare industry in India, he has received several awards including the Acharya PC Ray Memorial Gold Medal Award and the Eminent Pharmacist Award, the India Innovator Award at the India Business Leaders Awards instituted by CNBC. For his entrepreneurial vision, Mr. Patel was awarded the Ernst & Young Entrepreneur of the Year Award in the Life Sciences category
Sr Partner & Lead, Global Life Sciences Operations, McKinsey & Co
Parag is a Senior Partner with McKinsey & Co and co-leads the Life Sciences Operations practice globally. He has been with the firm for 15+ years and spends his time serving pharmaceutical & medical products companies across a wide range of topics including strategy, product development, procurement, manufacturing, quality, and supply chain.
Prior to McKinsey, Parag has spent 7 years at Merck & Co. in various roles in the US, the UK, and Singapore. Parag has a BS in Chemical Engineering from Cornell University, a MS in Chemical & Biomedical Engineering from UPENN, and an MBA from MIT Sloan School of Management.
Global Head of Operations, Sun Pharmaceutical Industries
Mr Rahul Awasthi is “Global Head of Operations” and part of management committee of Sun Pharma Industries Limited. Sun Pharma is the leader in Pharmaceutical space in India and 4 th Largest generic Pharma company Globally.
Sun Pharma has & 40 manufacturing locations spread across the globe and serve Billions of consumers across most of the markets globally. Product Development and Manufacturing is supported by state of art R&D infrastructure and thousands of scientists.
Rahul is a chemical engineer with 31 years’ experience in FMCG and Pharma sector. Prior to Sun pharma, He served at Leadership positions and Global roles in top FMCG multinationals like Hindustan Unilever Limited and Dabur India Limited.
He is a change agent with deep expertise in Manufacturing, Planning, Digital Transformation, Supply chain, Procurement, Quality, Sustainability.
Associate Professor, Department of Biosciences & Bioengineering, IIT Bombay
Dr. Rahul Purwar is a professor at Department of Biosciences and Bioengineering at IIT Bombay. He holds a Ph.D. in Molecular Medicine from Hannover Medical School, Germany. Dr. Rahul’s professional journey spans various prestigious institutions and roles. He started his post-doctoral fellowship at Harvard Medical School, Boston, USA. After his fellowship, he joined ImmunoGen, Inc. (Boston, USA), as a scientist before returning to India as a faculty member at IIT Bombay. His lab at IIT Bombay developed indigenous technology platform for CD19 CAR-T cell therapy, a type of gene therapy. Based on his research at IIT Bombay, Dr Purwar founded ImmunoACT in 2018, first cell & gene therapy company in India. Upon successful multiple clinical trials, ImmunoACT received market authorization of the country’s first CAR-T cell therapy, and Honorable President of India dedicated CAR-T cell therapy to the nation on April 4 th , 2024. This is the first of many planned milestones in democratizing access to advanced cell & gene therapies in India. Dr. Purwar’s research work is well-recognized in the scientific community, with numerous publications to his credit in esteemed journals. His contributions to the field of Biosciences & Bioengineering are commendable and his work continues to inspire many in the scientific community.
Drug Controller General of India, Government of India
Dr Raghuvanshi is the Drug Controller General of India – Government of India. He has experience of 32 Years / Drug Quality, Drug Regulatory, Drug Development. He is twice awarded with Dr. Reddy’s Lab Excellence award. 9 granted US patents. More than 60 publications in peer reviewed Journals & Co-Authored 6 chapters in books.
Dr. Raghuvanshi and his team developed more than 200 products which are currently sold globally. The Government of India has now given him the responsibility of Drugs Controller General of India. Currently contributing through leading the drug regulatory process in the country
Sr Technical Advisor, IPA
Dr Rajiv Desai is the Senior Technical Advisor at the Indian Pharmaceutical Alliance. He formerly headed the Corporate Quality Management at Lupin Ltd in India
Dr Rajiv Desai has around 30 years of experience in Pharmaceutical Industry. In his previous assignments, he has worked as heads of Corporate Quality Management at Dr Reddys, Mylan, Piramal and Alembic Pharmaceuticals. He started his career with Ciba Geigy (now Novartis) in R&D and Technology transfer in India and Switzerland.
His experience in the Pharmaceutical Industry spreads across basic research, Technology transfers, Quality Management and Regulatory affairs.
Selected as an US Pharmacopeia Expert committee between 2010 and 2015. He has been invited to deliver lectures at various international and national scientific forums. He has actively worked on several board of studies of reputed universities in India for short term teaching assignments and syllabus revision programs for post graduate courses. At UDCT, he was appointed as visiting faculty, under the Daiichi Karkaria memorial endowment faculty program for the year 2013 – 2014
Dr Rajiv Desai, has a Ph.D from UDCT ( now ICT) in Pharmaceutical Chemistry and a post graduate degree in Management from NMIMS.
Joint Drugs Controller India, CDSCO
Chandrashekar Ranga has more than 34 years’ experience in Drugs Control Departments of the State and Central Governments in various capacities He is currently heading Global Clinical Trials and Drug Safety, International Cell, Amendments to the sub-ordinate legislation, E-Governance, Ayush vertical, Legal Cell, etc. Further, he is the Chairman of the Technical Committee of the Strengthening of Pharmaceutical Industry Scheme of the DoP and Member, NPPA. He is the Central Licensing Approval Authority for Blood centre and blood components, Written Confirmation Certificate for export of API to EU and for permissions issued for CDSCO portals.
Earlier he was Head of New Drugs and Biologics. He played a key role in establishing relations with International Regulatory Agencies He has initiated the e-Governance program and Intelligence Cell at CDSCO. He was convener of various sub-Committees of the DCC leading to notification of the Rules
Chief Quality Officer, Lupin
Dr Ranjana is a seasoned pharmaceutical professional with over three decades of global experience. Her expertise lies in quality and related functions, and she currently oversees Lupin’s global quality operations. Before joining Lupin, Ranjana held the position of Global Head for Quality and Pharmacovigilance at Dr. Reddy’s. During her tenure, she was a key member of the Dr. Reddy’s Management Council, contributing to several positive outcomes for the company.
Her leadership journey extends across various branded and generic pharmaceutical companies, including Cipla, Actavis, Endo, Zenith Goldline, and Thames Pharmacal.
Ranjana’s academic achievements include a Doctorate in Health Administration from the University of Phoenix, USA, an MBA from Dowling College, New York, a Post-Graduate Diploma in Pharmaceutical & Chemical Analysis from Sophia College, Mumbai, and a B.Sc. (Hons) in Chemistry from Mithibai College, Mumbai. Additionally, she has received specialized training in pharmaceutical and biologics leadership at Harvard University
Chief Quality Officer, Sun Pharmaceutical Industries
Reem Malki joined Sun Pharma as the EVP and Chief Quality Officer in October 2023, overseeing all aspects of quality management. She is known for her strategic vision, focusing on continuous improvement and leveraging data-driven insights to enhance quality across the organization. Her passion is to ensure patient accessibility to high quality, affordable medicines and does this through fostering a strong culture of Quality. She believes that excellence is achieved not just through processes and systems, but through the empowerment and cross-functional engagement of employees at all levels, to ensure Quality is a collaborative practice by all. With a career marked by dedication, innovation, and a commitment to Quality and excellence, Reem continues to lead the way in Quality management and set new standards for the industry.
Reem joined Sun with over 30 years of Quality, Regulatory Compliance and Executive Leadership experience. Most recently, she was SVP and Chief Quality Officer at Amneal Pharmaceuticals and prior to that she was associated with Alvotech hf as CQO and a number of senior roles within the Mylan organization. Before Mylan, she held various diverse, technical roles at Andrx Pharmaceuticals, Inc., Zymark Corporation and Wyeth-Ayerst Pharmaceuticals. Reem holds a Bachelor of Science degree in Chemistry from the University of Maine.
EVP, Head of Supply Chain, GSK
Rishikesh is the EVP, Supply Chain Head for GSK India, Mumbai since January 2025 responsible for end to end supply chain for own mfg, external supply & Imports and accountable for delivering manufactured Gen Med, Specialties & Vaccines products and inter-plant services that meet safety, quality, cost and on-time delivery goals in support of associated business objectives.
Rishikesh previously worked for Baxter Pharmaceuticals and has 27+ years’ experience in pharmaceutical and vaccines manufacturing in FDA regulated facilities. His previous position was Site Director at the Baxter Facility at Ahmedabad.
Rishikesh has previous experience with GSK for 21+ yrs including 4 years at the Marietta (PA), USA vaccine manufacturing site & 6 years with Baxter Ahmedabad. His 27+ yrs of experience includes working in Operations, Quality, Project Management, Operational Excellence & Technical Trainings. Rishikesh holds a post graduate in Pharmaceutical Chemistry from, Indore, India.
Executive Vice President, Principal Consultant, NSF Health Sciences
Sam joined NSF from a long career history with the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the UK Department of Health & Social Care (DHSC). Most latterly, Sam was the Senior Responsible Owner for the £bn Social Care Reform programme across the UK at the DHSC, but the majority of Sam’s career has been spent in a variety of roles at the MHRA (from the Inspectorate to Board level). Before joining the DHSC, Sam was Chief Quality and Access Officer at the MHRA with accountability for regulatory activities across the UK supply chain, including Inspectorate (all GxPs), Enforcement, Licensing, Clinical Trials, Pharmacopoeia & pre-market Medical Device activities. Sam also brings extensive experience of crisis management, having led national and international scale incidents, and was the Executive lead for the MHRA’s response to the pandemic.
Sam has a doctorate in chemistry from the University of Reading and has also completed an MBA at Warwick University. Sam is also a dedicated mentor and coach.
Senior Partner, Economic Law Practice
Sanjay Notani is a Partner at ELP and co-heads the International Trade & Customs practice. He is a member of the Supreme Court Bar of India (SCBA) and Maharashtra & Goa Bar Council, American Bar Association (ABA) and has the distinction of being appointed in the Steering Group of the Export Controls and Economic Sanctions Committee; Member of the International Energy and Environmental Law Committee and South Asia/Oceania & India Committee of the ABA International Law Section. Additionally, Sanjay has been nominated by the Society of Indian Law Firms (SILF) to be a member on its Committee on Environment and Climate Change. Sanjay also provides trade advice on various FTA’s/RTA’s being negotiated and signed by India. Sanjay has in-depth experience in advising various multinational companies on import and export control as well as licensing issues, specifically the dual use of goods and technologies regulations (Export Control Regulations (SCOMET). Market Access Barriers in The Pharmaceutical Sector in India’s Key Export Destinations – This report, prepared by Economic Laws Practice (ELP) in collaboration with the Indian Pharmaceutical Alliance (IPA), examines the regulatory environment of some of India’s key trading partners. It identifies existing and potential trade barriers impacting pharmaceutical exports to these markets, serving as a ready reckoner and comprehensive guide for the pharmaceutical industry. Sanjay has been recommended for his expertise in Chambers Asia-Pacific, Chambers Global and Legal500 Asia- Pacific. He has been recognized as a Global Elite Thought Leader & Thought Leader: India by Lexology Index Trade & Customs and has featured in the WorldECR Awards He has also featured in the India Business Law Journal’s A List as India’s Top 100 Lawyers. He also features in LawWiser’s Lawyers Power League: 100 Leading Law Firm Professionals of 2023.
Head Global Operations, Dr Reddy’s Laboratories
Sanjay is a Transformational Leader with close to 32 years in the FMCG & Pharmaceuticals industry handling diverse set of roles spanning across Manufacturing, Supply Chain, Procurement, Sales, Portfolio Management and ESG in both emerging and developed markets, in a cross-cultural environment. In his present role, he is the Head of Global Operations and leads the Product Selection to Commercialization, end to end Operations and ESG for Dr Reddy’s. The operations footprint includes 23 plants in India, US, UK, Mexico & China.
Sanjay holds a Bachelor’s degree in Chemical Engineering from IIT Delhi, and General Management from IIM Ahmedabad. He recently completed the Advanced Management Program (AMP) at Harvard Business School.
CEO & Whole-time Director, Gennova Biopharmaceuticals
Dr. Sanjay Singh is the CEO of Gennova Biopharmaceuticals Ltd, Pune, India. As a CEO since 2006 at Gennova, Dr. Singh has focused on innovations in bio-manufacturing technologies that culminated in the commercialization of seven life-saving bio-therapeutics in the cardiovascular, neurology, nephrology, and oncology markets. His scientific background has enabled and fostered a research environment. Dr. Singh has led Gennova to develop India’s first mRNA-based vaccine, which got the Emergency Use Authorization (EUA) Dr. Singh has played a significant role in bridging the gap between industry and academia collaboration as he is currently a member of various important national relevant committees, including the Scientific Advisory Board of the NCCS – Pune, CMBR – Lucknow, TIGS – Bengaluru. Dr. Singh is also a member of the National Committee for Biotechnology- Confederation of Indian Industry, New Delhi. Dr. Singh holds a Ph.D. in Biochemistry from the Central Drug Research Institute (CDRI), Lucknow, India. Before joining Gennova, he headed the Antigen Research Section at the Malaria Vaccine Development Unit of the National Institutes of Allergy and Infectious Diseases, NIH, USA.
President, Zydus Research Centre - Biotech, Zydus
Dr Sanjeev Kumar is President at Zydus Lifesciences Ltd., heading the Research and drug substance Manufacturing efforts in Biologics. Under his leadership Zydus has developed and launched 14 Biosimilars and 1 novel biologic drug along with an equally large number in pipeline. He has been doing drug development for close to 28 years now spanning Biosimilars and Novel Biologics for around 22 years at Zydus and gene therapies at multiple companies in the US for 6 years. Dr Kumar is trained as an immunologist with a PhD at the National Institute of Immunology, Delhi and Postdoc at Vanderbilt University, Nashville, Tennessee.
Sr Partner & Lead, Asia Life Sciences, McKinsey & Co
Sathya is a Senior Partner with McKinsey & Company. He leads the Pharmaceuticals and Life Sciences Practice across Asia and is a leader in McKinsey’s global healthcare operating committee. Sathya, was part of the founding team of McKinsey’s Pharmaceutical Generics practice globally and led the global Generics practice for McKinsey for over 8 years.
Over his career spanning two decades, Sathya has served over 50 pharmaceutical companies across China, India, Rest of Asia, Western Europe and the Americas, during which period he has been part of over 20 company transformations.
Sathya has been a speaker at the India summit at Harvard Business School, the Google-McKinsey digital health conference and a keynote at several generic conferences globally. He was awarded the Young business leader award in 2005 and the ET 40 under 40 in 2020.
Prior to joining Mckinsey, Sathya has worked with the Goldman Sachs & Co. in London and has a Post Graduate Diploma in Management from the Indian Institute of Management-Bangalore (IIMB).
Sr Vice President and Head, Global Supply Chain, Lupin
Mr. Saurabh Gupta is the Global Head Supply Chain at Lupin Ltd. He leads Supply Chain operations for all the markets and responsible for Demand Planning, Supply Planning, Logistics and New Launches for API and Formulation Products. Prior to this, he was associated with AkzoNobel Ltd for 10 years, heading South Asia Supply Chain role for multiple plants and countries. He also served as Plant Head followed by Supply Chain Head role for Country operations. He has exposure in Manufacturing, Supply Chain, Operational Excellence, Integrated Business Planning (IBP) roles. He started his corporate career with Asian Paints Ltd where he joined as Management Trainee and later took up role of Production Manager, Projects Management and Supply Chain Distribution. Saurabh earned a Bachelor’s degree in Marine Engineering and has been a sailor on merchant vessels. He completed his full-time MBA program from NMIMS, Mumbai and Executive Program from ISB, Hyderabad. He likes to travel places to absorb different culture, enjoys sports like volleyball & tennis, and an amateur photographer.
Sr Technical Advisor, IPA
Education :- Post graduate degree in Pharmacy alongwith Diploma in Business Management &. Certification in general management from IIM Ahmedabad Experience :- Total experience of 42 years in managing pharmaceutical manufacturing Curently he is supporting the activities of Quality Forum of Indian Pharmaceutical Alliance as Senior Technical Advisor
Earlier he was Managing Director – Zydus Hospira Oncology P.Ltd., (ZHOPL) – A joint venture company of Zydus & Pfizer for Manufacturing and distributing sterile oncological injectables. This company exports Oncology injectables to 61 countries including USA, Japan & Europe with highest regulatory compliance and quality standards.(August 2016 till December 2019)
Prior to this job he was responsible for all the global manufacturing functions of Zydus Cadila from February’2001 till July’2016 as President Global Manufacturing. He was also a member of Executive Committee of Zydus.
His previous experience includes working in reputed companies FDC, Cipla, Cynamid and Sun Pharma in various capacities and departments.
Vice President, Safety & Sustainability, Jubilant Ingrevia
A professional with >2 decades of experience in Chemicals, Pharma, Oil & Gas and Foods sectors across Europe, USA and Asia in Manufacturing, Projects, Engineering, EHS and ESG disciplines.
He currently is the Vice President – ESG and EHS at Jubilant Group. Has worked as Executive Vice President in SIL and leadership positions in Cipla, Mondelez and Shell. He is also member of various committees and affiliations. Currently he is in the ESG Advisory Committee of SEBI (Securities and Exchange Board of India) and ASSOCHAM.
Building strong Engineering, Operational Excellence and EHS teams. Create and drive strategies on Safety, ESG, Engineering and Occupational Health/Industrial Hygiene for Cultural Transformation towards best in class. Led Digitization, Automation & Industry 4.0 for the enterprises.
Sharad has graduated in Chemical Engineering and holds Masters in Petroleum and Reservoir Engineering.
Has received External recognition for making enterprise Carbon Positive, Water Positive, Zero Water Discharge & Waste to Landfill with best-in-class Safety culture.
Likes running, avid marathoner and travel with family and friends.
Vice President, IPA and Managing Director, Zydus Lifesciences
Dr. Sharvil Patel is the Managing Director of Zydus Lifesciences Ltd., a global innovation-driven lifesciences company which has a legacy of over 70 years in the field of healthcare. The group was founded by Mr. Ramanbhai Patel in 1952. Today, the group researches, develops, manufactures and markets wide ranging therapeutics, biologicals and vaccines. Besides this, the group is into high-end diagnostics to detect cancers. Dr. Sharvil Patel, a third generation entrepreneur, also officiates as the Chairman on the Board of Zydus Wellness Ltd., which is creating several novel experiences for the health-conscious consumers and has a basket of niche products and iconic brands. With a specialisation in Chemical and Pharmaceutical Sciences from the University of Sunderland, U.K., and a doctorate also from the same university for his research work in Breast Cancer at Johns Hopkins, Bayview Medical Centre, USA, Dr. Sharvil combines both pharma and research expertise.
Dr. Sharvil Patel’s leadership has inspired the organization to explore an expansive canvas of thoughts and ideas which are patient-centric, innovative and futuristic. With a turnover of over $2.35 bn, Zydus today has a global presence in over 75 countries worldwide including Asia, Europe, Latin America, MENA, North America. In the US and Europe, the group has been contributing to health and well-being since the last two decades. As an innovation driven organization, Zydus has been bringing in several novel NCEs, novel biologicals, biosimilars and vaccines to the market including the world’s first plasmid DNA vaccine ZyCoV-D to fight Covid-19. The group offers path-breaking discoveries for diseases such as Metabolic Associated Fatty Liver Disease (MAFLD), Metabolic dysfunction-associated Steato Hepatitis (MASH), Cancer, Chronic Kidney Disease, amongst others. With a network of 37 manufacturing plants which includes 16 USFDA inspected facilities and 8 research and development centres, the group is powered by 27000 people worldwide. Dr. Sharvil Patel is also on the Board of Zydus Foundation which spearheads programmes related to healthcare, education, community development through livelihood programme and supporting grassroots innovation. Zydus Foundation supports the Zydus Medical College and Hospital which offers free of cost treatment to villagers in Dahod, a remote tribal village in Western Gujarat. At the 1000 bed hospital, all treatments and services are free of cost. More than 450,000 OPD patients avail treatment and more than 88000 surgeries are also conducted each year at the hospital.
Dr. Sharvil Patel is the Honorary Consul of Belgium and also the Vice President of the Indian Pharmaceutical Alliance. He is an additional Independent Director of Gujarat Mineral Development Corporation Limited (GMDC). He has been conferred the ET Pharmaleader of the year at the ET Healthworld India Pharma Awards 2022. He has also been conferred the ‘The Economic Times Most Promising Business Leaders of Asia 2020-21’ Award,’ GenNext Entrepreneur of the Forbes India Leadership Awards (FILA) 2020-21’ by the Forbes India and ‘Young Turks Award’ by India Pharma Awards 2021. He received the ‘40 Under 40 Most Influential Asians’ Award by the Asian Business & Social Forum 2018 (ABSF) and the Young Business Leader ’40 under Forty’ Award by ET Now in 2017.
Chairman, Bosch and CEO & Executive Director, Indian Foundation for Quality Management (IFQM)
Soumitra Bhattacharya, with a rich tenure of over 40 years of which 28 years traversed at Bosch – in various function eg. VP Plant Management to assignments in Germany and Turkey and continuing at Bosch Ltd. as the Chief Financial Officer (CFO) from 2011 to 2016 and then as Joint Managing Director (2012-2016) and later as Managing Director (2017-2023) and as the Regional President for the Bosch Group in India until his retirement on June 30, 2023. His portfolio encompassed the entire responsibility for Bosch India. On a personal front, Soumitra, married to Dr. (Mrs.) Chandana Bhattacharya (Founder and Trustee for Ekakanya Trust), is a father of two and the couple’s adorable golden retrievers with a penchant for travel, social service, deep interest in intercultural activities and Nation First activities.
His commitment to industry excellence continued post-retirement when he assumed the role of CEO and Director at Indian Foundation for Quality Management (IFQM) in July 2023, an initiative driven by Captains of Industry centered around Quality, Excellence, and Innovation on a Nation First approach.
Soumitra continues his association with Bosch in India as the Chairman of the Board of Bosch Ltd (Non-Executive), as Independent Director of Asian Paints Ltd., as an Additional Director (Non-Executive Independent) of Tata Elxsi Ltd. And as a Nominee Director of Tata Indian Institute of Skills, Chairman of CII-IQ & Advisory Board on Corporate Governance for IIMB.
Before his time at Bosch, with key management roles at TATA Steel, IPITATA, INDAL, and as one of the starting members for Tanishq of Titan Company Limited. A Chartered Accountant by profession, his academic foundation was laid at The Institute of Chartered Accountants of India, where he completed his article-ship from Price Waterhouse.
Concurrently, he has been a significant part of the Confederation of Indian Industry (CII), chairing the Karnataka State Council for CII in India (2013-2014), co-chairing for CII-National Skills Committee (2017-2019), chairing the CII National Committee on MNCs (2020-2023), and contributing passionately towards business excellence and corporate agility from 2013 to 2023. Soumitra is currently the Chair of the CII Institute of Quality Advisory Council for the year 2024-25.
He has spoken extensively in India and across the world on various platforms – Social and Corporate, on topics which he is passionate – Quality, Business Excellence, Innovation, and Business Strategy.
Global Chief Human Resources Office, Sun Pharma
In a career spanning over three decades; Suresh has worked with Unilever and Procter & Gamble and is now associated with Sun Pharma as Global CHRO.
In his 25+ years of association with Unilever, he held number of Senior Leadership roles which included CHRO – Global Nutrition, Global Vice President- Foods & Refreshment, Vice President Human Resources – South-East Asia & Australasia, Vice President Human Resources – Unilever Philippines, Leadership & Organization Development Director – Global Markets. Prior to Unilever, he was associated with Procter and Gamble in supply chain.
A C-suite Human Resources leader with global experience in consumer business with proven impact across HR strategy, M&A and disposals, creating high performing organizations, leadership pipelines, establishing agile workplaces, building digital, data and global capability centers. He has lived-in multi-country experience. Suresh is a contributor on diverse topics in different forums & business bodies including INSEAD, HCLI- Singapore. He was also a guest speaker at Vietnam National HRD Conference, University of Amsterdam, and was instrumental in establishing Industry Digital HR Forum in the Philippines. He was recognised amongst 12 Stellar HR leaders in Asia Hot List of HRD Asia magazine. Suresh holds an MBA in HR from XLRI Jamshedpur and B Tech in Electrical Engineering from IIT Delhi.
He loves traveling, astronomy and reading about military history.
Secretary General, Indian Pharmaceutical Alliance
Sudarshan has a strong passion for healthcare and the education sector. He is currently the Secretary General of the Indian Pharmaceutical Alliance (IPA), Senior Advisor with APAX Partners and the Chairman of the Indian Institute of Health Management and Research (IIHMR), Jaipur. He also serves as a Board Member of Abbott India, Sunshine Holdings PLC and various educational institutions.
Sudarshan is on the Advisory Committee of the Biotechnology Ignition Grant, Government of India and a Visiting Faculty at the Indian Institute of Management Ahmedabad (IIM A). He is a Certified Executive Coach from the Coaching Foundation of India.
Sudarshan has a rich healthcare business experience of over 45 years and has contributed to shaping healthcare policy and improving access to healthcare in India. He has held several leadership positions in Abbott, J&J, Boots and leading Indian companies and last served as the Managing Director at Abbott Healthcare Solutions. His experience spans across Pharmaceutical, OTC, Hospital, Diagnostic and Nutrition businesses. He has been associated with over 30 brands which are among the top 300 in the Indian pharmaceutical market. He also served as Chairman of the Life Sciences Skill Sector Development Council (LSSSDC) of India under the Ministry of Skill Development & Entrepreneurship. He has been the Chair of International Generic and Biosimilar Medicines Association (IGBA).He is the first Indian recipient of the Global Chairman’s Award at Abbott. Sudarshan is an alumnus of St. Stephens College, Delhi and Indian Institute of Management, Ahmedabad (IIM A).
Lead Senior GMDP Inspector, MHRA
Trevor is a Lead Senior GMP Inspector, with over 10 years at MHRA. His role includes inspecting UK and overseas manufacturing sites. He is also the GMP technical lead for importation, for qualified persons, and medicinal gases. He previously worked in the UK pharmaceutical industry for over 25 years in various QC and QA roles and was a Qualified Person on both MIA and MIA(IMP) licences.
Managing Director and Global CEO, Cipla
Umang Vohra is the Managing Director and Global Chief Executive Officer (MD & GCEO) of Cipla since September 2016. Umang joined Cipla in October 2015 as its Global Chief Financial Officer, and from January 2016 to August 2016 he was Cipla’s Global Chief Operating Officer.
Under Umang’s leadership, Cipla has built strong momentum in its home markets, augmented its capabilities, strengthened its core, and shown significant improvement in its operating margin and profitability. At the helm of the Management Council, Umang is currently steering Cipla’s ambition of becoming a leading global healthcare organization, underpinned by innovation and digital transformation. Known for his proactive approach and recognised as an action-oriented industry leader, Umang is a firm believer in the power of agile business models, disruptive technologies, data-driven analytics, and a future-ready workforce. His approach to shaping the healthcare ecosystem goes beyond the pursuit the profit, focusing on compassion and humanitarian values. Umang’s big-picture agenda is to define and execute Cipla’s strategic growth roadmap and geographical footprint, identify the next levers of growth, invest in innovation for the future, and build a future-fit organisation, while also ensuring that Cipla consistently upholds its commitment to providing patients and consumers with the highest quality of care.
Umang’s distinguished career spanning close to three decades includes roles in both India and the USA. He has been associated with renowned companies such as Eicher Motors and PepsiCo and Dr. Reddy’s Laboratories. Umang’s impressive academic background includes degrees in engineering, marketing, and finance.
Partner & Lead, North America Lifesciences Manufacturing and Supply Chain, McKinsey & Co
Partner & Lead, North America Lifesciences Manufacturing and Supply Chain, McKinsey & Co
Vivek is a Partner based out of McKinsey & Co’s Boston office, and leads the Manufacturing, Supply Chain and Digital Operations practice within Life Sciences. Vivek is one of the founding members for the IPA Quality Forums and was instrumental in setting its vision.
He has been with the firm for 14+ years and has worked across India (Delhi) and US (Boston) offices. Vivek’s clients include big pharma companies, mid-size pharma and med-tech players, global generics and specialty firms, life-sciences-focused PE-firms, CDMOs, CROs, Biotechs, and industry associations. His work with them includes end-to-end performance transformation, innovation acceleration, network strategy, digital transformation, operations excellence, growth strategy and operating model.
Vivek holds an MBA from ISB Hyderabad and a B.Tech in Electrical Engineering from IIT Kanpur.
27 February 2025 - 28 February 2025 
JW Marriott Juhu, Mumbai
